ACADIA Pharmaceuticals Inc.

As you may have heard by now, ad revenue alone isn't enough to sustain ongoing efforts to improve our service, which is why we are asking loyal site users like you for help. For every $25 contribution, we're offering 3 months of premium service on a "non-recurring" basis. By reducing the need to click, scroll and wait for pages to load, some of our most popular features save premium members considerable time on every visit. Imagine saving even 2 or 3 minutes each day (to say nothing of 5 or 10 or more). Of course, only you know what your time is worth, so we'll let you do the math & figure out if a test drive makes sense for you. To learn more, click this link to watch a 2-min video tour of our premium service.

CLICK HERE to take advantage of this special offer by making a one-time contribution on our secure payment page

ACAD / Message Board / Read Message

Keyword
Subject

Between			and
Rec'd By

Authored By
Minimum Recs

Msg 15693 of 15779 at 9/19/2019 5:11:09 PM by

In response to msg 15692 by Nazaretti	view thread

ACAD said in the conf call that ~67% of the DRP PhIII enrollees were ADP diagnosis.

That would be a fair assumption.

| More

Recs: 1 Views: 324


	About Us • Contact Us • Follow Us on Twitter • Members Directory • Help Center • Advertise Not a member yet? What are you waiting for? Create Account Want to contribute? Support InvestorVillage by donating © 2003-2019 Investorvillage.com. All rights reserved. User Agreement